Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis

NCT02497976 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Cystitis, Interstitial

Interventions

BIOLOGICAL: Certolizumab pegol
DRUG: Placebo

Sponsor

ICStudy, LLC

Collaborators

[object Object]